It’s the first study to demonstrate cardiovascular risks of high doses of ketamine (low blood pressure, arrhythmia), side effects that have not been well studied in the past.
Vanderbilt-Ingram Cancer Center accrued the most patients nationwide for the clinical trial for P-BCMA-ALLO1 – a chimeric antigen receptor T cell therapy (CAR-T) derived from healthy donors’ white blood cells.
A new study identifies previously unreported protein biomarkers and candidate drug targets across six major cancer types and highlights approved drugs with potential cancer preventive effects.
In a large, placebo-controlled, randomized trial, the pain reliever ketamine posed side effects while failing to aid patient recovery after major surgery.
Study showed that the improvement in lung cancer screenings exceeded the target enrollment set by the researchers.
Researchers hope to slow the progression of this chronic eye disease that affects approximately 40% of the U.S. population.